Implementation and Operational Research: Programmatic Feasibility of Dried Blood Spots for the Virological Follow-up of Patients on Antiretroviral Treatment in Nord Kivu, Democratic Republic of the Congo

Journal of Acquired Immune Deficiency Syndromes

Volumn 71, Issue 1, 2016, Pages e9-e15

  Boillot, François ^a   Serrano, Laetitia ^b   Muwonga, Jeremie ^c   Kabuayi, Jean Pierre ^c   Kambale, Alain ^c   Mutaka, Fidèle ^c   Fujiwara, Paula I ^d   Decosas, Josef ^e   Peeters, Martine ^b   Delaporte, Eric ^b  

^a Alter Santé Internationale and Développement   (France)

^b UNIV MONTPELLIER   (France)

^c Kinshasa Gombe and Goma   (France)

^d INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

^e HERA   (Belgium)

Author keywords

ART monitoring; Democratic Republic of Congo; dried blood spots; HIV; programmatic context; viral load assay

Indexed keywords

ANTIRETROVIRUS AGENT; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; COST EFFECTIVENESS ANALYSIS; DEMOCRATIC REPUBLIC CONGO; DRIED BLOOD SPOT TESTING; FEMALE; FOLLOW UP; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIMARY HEALTH CARE; PRIORITY JOURNAL; QUALITY CONTROL; TURNAROUND TIME; WORLD HEALTH ORGANIZATION; ANTIVIRAL RESISTANCE; BLOOD; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; MIDDLE AGED; PROCEDURES; SYSTEM ANALYSIS; VIROLOGY; VIRUS LOAD;

ADULT; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BLOOD; DEMOCRATIC REPUBLIC OF THE CONGO; DRIED BLOOD SPOT TESTING; DRUG RESISTANCE, VIRAL; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; OPERATIONS RESEARCH; VIRAL LOAD;

EID: 84983097411     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000844     Document Type: Article

References (33)

1. The Union. Management of Tuberculosis. A Guide to the Essentials of Good Practice. 6th ed. Paris, France: IUATLD; 2010. Available at: http://www.theunion.org/what-we-do/publications/technical/management-oftuberculosis-A-guide-to-the-essentials-of-good-clinical-practice. Accessed February 24, 2015.
2. World Health Organization. Task Shifting: Rational Redistribution of Tasks Among Health Workforce Teams. Geneva, Switzerland: 2008. Available at: http://www.who.int/healthsystems/TTR-TaskShifting.pdf. Accessed February 24, 2015.
3. World Health Organization. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection. Recommendations for a Public Health Approach. Geneva, Switzerland: 2013. Available at: http://www.who.int/hiv/pub/guidelines/arv2013/download/en/. Accessed February 24, 2015.
4. UNAIDS. HIV and AIDS estimates (2013). Available at: http://www. unaids.org/en/regionscountries/countries/democraticrepublicofthecongo. Accessed February 20, 2015.
5. Johannessen A. Dried blood spots in HIV monitoring: applications in resource-limited settings. Bioanalysis. 2010;2:1893-1908.
6. World Health Organization. Guidance on Regulations for the Transport of Infectious Substances 2013-2014. Geneva, Switzerland: 2012. Available at: http://www.who.int/ihr/publications/who-hse-ihr-2012.12/en/. Accessed February 20, 2015.
7. Lofgren SM, Morrissey AB, Chevallier CC, et al. Evaluation of a dried blood spot HIV-1 RNA program for early infant diagnosis and viral load monitoring at rural and remote healthcare facilities. AIDS. 2009;23:2459-2466.
8. Monleau M, Butel C, Delaporte E, et al. Effect of storage conditions of dried plasma and blood spots on HIV-1 RNA quantification and PCR amplification for drug resistance genotyping. J Antimicrob Chemother. 2010;65:1562-1566.
9. Monleau M, Montavon C, Laurent C, et al. Evaluation of different RNA extraction methods and storage conditions of dried plasma or blood spots for human immunodeficiency virus type 1 RNA quantification and PCR amplification for drug resistance testing. J Clin Microbiol. 2009;47: 1107-1118.
10. World Health Organization. Health Technology Assessment of Medical Devices (WHO Medical Device Technical Series). Geneva, Switzerland: 2011. Available at: http://whqlibdoc.who.int/publications/2011/9789241501361-eng.pdf. Accessed February 24, 2015.
11. Stevens W, Gelman R, Glencross DK, et al. Evaluating new CD4 enumeration technologies for resource-constrained countries. Nat Rev Microbiol. 2008;6:S29-S38.
12. Tugwell P, de Savigny D, Hawker G, et al. Applying clinical epidemiological methods to health equity: the equity effectiveness loop. BMJ. 2006;332:358-361.
13. Parkin NT. Measurement of HIV-1 viral load for drug resistance surveillance using dried blood spots: literature review and modeling of contribution of DNA and RNA. AIDS Rev. 2014;16:160-171.
14. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1:307-310.
15. Chalkidou K, Marten R, Cutler D, et al. Health technology assessment in universal health coverage. Lancet. 2013;382:e48-e49.
16. The Global Fund. Report of the technical review panel and the secretariat on round 10 proposals, 2010. Available at: http://www.theglobalfund. org/en/trp/reports/. Accessed February 24, 2015.
17. Greig J, du Cros P, Klarkowsi D, et al. Viral load testing in a resourcelimited setting: quality control is critical. J Int AIDS Soc. 2011;14:23.
18. Gericke CA, Kurowski C, Ranson MK, et al. Intervention complexity- a conceptual framework to inform priority-setting in health. Bull World Health Organ. 2005;83:285-293.
19. Petti CA, Polage CR, Quinn TC, et al. Laboratory medicine in Africa: a barrier to effective health care. Clin Infect Dis. 2006;42:377-382.
20. Alvarez M, Chueca N, Guillot V, et al. Improving clinical laboratory efficiency: introduction of systems for the diagnosis and monitoring of HIV infection. Open Virol J. 2012;6:135-143.
21. Monleau M, Aghokeng A, Eymard-Duvernay S, et al. Field evaluation of dried blood spots for routine HIV-1 viral load and drug resistance monitoring in patients receiving antiretroviral therapy in Africa and Asia. J Clin Microbiol. 2014;52:578-586.
22. Klarkowski DB,Wazome JM, Lokuge KM, et al. The evaluation of a rapid in situ HIV confirmation test in a programme with a high failure rate of the WHO HIV two-test diagnostic algorithm. PLoS One. 2009;4:e4351.
23. Aghokeng AF, Mpoudi-Ngole E, Dimodi H, et al. Inaccurate diagnosis of HIV-1 Group M and O is a key challenge for ongoing universal access to antiretroviral treatment and HIV prevention in Cameroon. PLoS One. 2009;4:e7702.
24. Shanks L, Klarkowski D, O'Brien DP. False positive HIV diagnoses in resource limited settings: operational lessons learned for HIV programmes. PLoS One. 2013;8:e59906.
25. Thapa B, Koirala S, Upadhaya B, et al. National external quality assurance scheme for HIV testing using dried blood spot: a feasibility study. SAARC journal of tuberculosis, lung diseases and HIV/AIDS. 2011;8:23-27.
26. Bennett DE, Jordan MR, Bertagnolio S, et al. HIV drug resistance early warning indicators in cohorts of individuals starting antiretroviral therapy between 2004 and 2009: World Health Organization global report from 50 countries. Clin Infect Dis. 2012, 54(suppl 4): S280-S289.
27. World Health Organization. Surveillance of HIV Drug Resistance in Adults Receiving ART (Acquired HIV Drug Resistance). Geneva, Switzerland: 2014. Available at: http://apps.who.int/iris/bitstream/10665/112801/1/9789241507073-eng.pdf?ua=1. Accessed February 24, 2015.
28. Kahn JG, Marseille E, Moore D, et al. CD4 cell count and viral load monitoring in patients undergoing antiretroviral therapy in Uganda: cost effectiveness study. BMJ. 2011;343:d6884.
29. Boyer S, March L, Kouanfack C, et al. Monitoring of HIV viral load, CD4 cell count, and clinical assessment versus clinical monitoring alone for antiretroviral therapy in low-resource settings (Stratall ANRS 12110/ESTHER): a cost-effectiveness analysis. Lancet Infect Dis. 2013;13:577-586.
30. Ainsworth M, Teokul W. Breaking the silence: setting realistic priorities for AIDS control in less-developed countries. Lancet. 2000; 356:55-60.
31. Marseille E, Hofmann P, Kahn J. HIV prevention before HAART in sub-Saharan Africa. Lancet. 2002;359:1851-1856.
32. Keebler D, Revill P, Braithwaite S, et al. Cost-effectiveness of different strategies to monitor adults on antiretroviral treatment: a combined analysis of three mathematical models. Lancet Glob Health. 2014;2:e35-e43.
33. UNAIDS. Landmark HIV diagnostic access program will save $150m and help achieve new global goals on HIV. 2014. Available at: http://www. unaids.org/en/resources/presscentre/pressreleaseandstatementarchive/2014/september/20140925prviralload. Accessed February 24, 2015.